PUBLICATIONS
Evans JW, Szczepanik J, Brutsche N, Park LT, Nugent AC, Zarate CA, Jr. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. Biol Psychiatry. 2018 Feb 15.
Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard Ed, Zarate CA Jr. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord. 2018 May;232:310-315.
Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. 2018 Feb 27.
Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA Jr. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. J Psychopharmacol. 2017 Dec;31(12):1570-1577.
Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, Ameli R, Niciu MJ, Brutsche NE, Park L, Zarate CA Jr. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. J Affect Disord. 2017 Aug 15;218:195-200.
Duncan WC Jr, Slonena E, Hejazi NS, Brutsche N, Yu KC, Park L, Ballard ED, Zarate CA Jr. Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine’s Rapid Antidepressant Properties. Biol Psychiatry. 2017 Sept 1; 82(5):361-369.
Ballard ED, Luckenbaugh, DA, Richards, EM, Walls, TL, Brutsché, NE, et. Al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatric Res. 2015;68;68-73.
Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh, DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr. Lithium and Valproate Levels Do Not Correlate with Ketamine’s Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plast. 2015 June 7.
Luckenbaugh DA, Ameli R, Brutsche NE, Zarate CA Jr. Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. J Psychiatr Res., 2015 Feb;61:40-5.
Niciu MJ, Luckenbaugh, DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr. Ketamine’s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. 2014 Oct 31;18(1).
Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Sloena EE, Vande Voort JL, Brutsche NE, Zarate CA Jr. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014 Sept:75(9).
Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey ML, Zarate CA Jr. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014 Nov;58;161-6.
Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr. Riluzole likely lacks antidepressant efficacy in ketamine non-responders. J Psychiatr Res. 2014 Nov;58197-9.
Moaddel R, Luckenbaugh DA, Xie Y, Villasenor A, Brutsche NE, et. Al. D-serine plasma concentration is a potential biomarker of (R.S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl). 2015 Jan;232(2);399-409.
Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate CA Jr. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014 May;75(5).
Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et. Al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014 Apr;159:56-61.
Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L. Luckenbaugh DA, Brutsche N, et. Al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014 Mar;16(2):119-28.
Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, et. Al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013 Jun 15;73(12):1213-21.
Zeng MC, Niciu MJ, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Franco-Chaves J, Brutsche NE, Zarate CA Jr. Acute Stress Symptoms Do Not Worsen in Posttraumatic Stress Disorder and Abuse with a Single Subanesthetic Dose of Ketamine. Biol Psychiatry. 2013 June 15;73(12):e37-8.
Zarate, Ca Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA. A randomized trial of a low-trapping nonselective N-methl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013 Aug 15;74(4):257-64.
Luckenbaugh DA, Ibrahim L, Brutsche N, et. Al. Family history of alcohol dependence and antidepressant response to an N-methl-D-aspartate antagonist in bipolar depression. Bipolar Disord. 2012 Dec;14(8):880-7.
Duncan WC Jr, Selter J, Brutsche N, et. Al. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord, 2013 Feb 15;145(1):115-9.
Laje G, Lally N, Mathews D, Brutsche N, et. Al. Brain-derived neurotropic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012 Dec 1;72(11):e27-8.
Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, Potter WZ, Zarate CA Jr. A Randomized, Placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012 Aug;32(4):551-7.
Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11.
Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, et. Al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012 Oct1;72(7):555-61.
Zarate CA Jr, Brutsche N, et. Al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012 Aug 15;72(4):331-8.
Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji JK, Zarate CA Jr. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012 May;37(6):1526-33.
Zarate CA Jr, Brutsche NE, et. Al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012 Jun 1;71(11):939-46.
Zhao X, Venkata SL, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, Zarate CA Jr, Mager DE, Wainer IW. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol. 2012 Aug;74(2):304-14.
DiazGranados, N, Ibrahim, L, Brutsché, N, et. Al. A randomized add-on trial of an N-methyl-D-aspartate (NMDA) antagonist in treatment –resistant bipolar depression. Archives of General Psychiatry. 2010 Aug;67(8): 793-802.
DiazGranados N, Ibrahim L, Brutsche N, Ameli R, Henter I, Luckenbaugh D, Machado-Vieira R, Zarate CA. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010 Dec;71(12):1605-11.
Machado-Vieria R, Yuan P, Brutsché N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D aspartate antagonist. J Clin Psychiatry. 2009 Dec;71(12):1662-6.
Phelps, LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family History of Alcohol Dependence Predicts and Initial Antidepressant Response to an NMDA Antagonist. Biological Psychiatry. 2009 Jan;65(2):181-4.
Zarate, C.A., Jr., Singh, J.B., Carlson, P., Brutsché, N., Ameli, R., Luckenbaugh, D.A., Charney, D.S., & Manji, H.K. A randomized trial of an NMDA antagonist in treatment resistant major depression. Archives of General Psychiatry. 2006 Aug;63(8): 856-864.
Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard Ed, Zarate CA Jr. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord. 2018 May;232:310-315.
Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. 2018 Feb 27.
Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA Jr. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. J Psychopharmacol. 2017 Dec;31(12):1570-1577.
Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, Ameli R, Niciu MJ, Brutsche NE, Park L, Zarate CA Jr. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. J Affect Disord. 2017 Aug 15;218:195-200.
Duncan WC Jr, Slonena E, Hejazi NS, Brutsche N, Yu KC, Park L, Ballard ED, Zarate CA Jr. Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine’s Rapid Antidepressant Properties. Biol Psychiatry. 2017 Sept 1; 82(5):361-369.
Ballard ED, Luckenbaugh, DA, Richards, EM, Walls, TL, Brutsché, NE, et. Al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatric Res. 2015;68;68-73.
Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh, DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr. Lithium and Valproate Levels Do Not Correlate with Ketamine’s Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plast. 2015 June 7.
Luckenbaugh DA, Ameli R, Brutsche NE, Zarate CA Jr. Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. J Psychiatr Res., 2015 Feb;61:40-5.
Niciu MJ, Luckenbaugh, DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr. Ketamine’s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. 2014 Oct 31;18(1).
Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Sloena EE, Vande Voort JL, Brutsche NE, Zarate CA Jr. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014 Sept:75(9).
Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey ML, Zarate CA Jr. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014 Nov;58;161-6.
Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr. Riluzole likely lacks antidepressant efficacy in ketamine non-responders. J Psychiatr Res. 2014 Nov;58197-9.
Moaddel R, Luckenbaugh DA, Xie Y, Villasenor A, Brutsche NE, et. Al. D-serine plasma concentration is a potential biomarker of (R.S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl). 2015 Jan;232(2);399-409.
Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate CA Jr. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014 May;75(5).
Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et. Al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014 Apr;159:56-61.
Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L. Luckenbaugh DA, Brutsche N, et. Al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014 Mar;16(2):119-28.
Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, et. Al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013 Jun 15;73(12):1213-21.
Zeng MC, Niciu MJ, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Franco-Chaves J, Brutsche NE, Zarate CA Jr. Acute Stress Symptoms Do Not Worsen in Posttraumatic Stress Disorder and Abuse with a Single Subanesthetic Dose of Ketamine. Biol Psychiatry. 2013 June 15;73(12):e37-8.
Zarate, Ca Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA. A randomized trial of a low-trapping nonselective N-methl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013 Aug 15;74(4):257-64.
Luckenbaugh DA, Ibrahim L, Brutsche N, et. Al. Family history of alcohol dependence and antidepressant response to an N-methl-D-aspartate antagonist in bipolar depression. Bipolar Disord. 2012 Dec;14(8):880-7.
Duncan WC Jr, Selter J, Brutsche N, et. Al. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord, 2013 Feb 15;145(1):115-9.
Laje G, Lally N, Mathews D, Brutsche N, et. Al. Brain-derived neurotropic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012 Dec 1;72(11):e27-8.
Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, Potter WZ, Zarate CA Jr. A Randomized, Placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012 Aug;32(4):551-7.
Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11.
Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, et. Al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012 Oct1;72(7):555-61.
Zarate CA Jr, Brutsche N, et. Al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012 Aug 15;72(4):331-8.
Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji JK, Zarate CA Jr. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012 May;37(6):1526-33.
Zarate CA Jr, Brutsche NE, et. Al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012 Jun 1;71(11):939-46.
Zhao X, Venkata SL, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, Zarate CA Jr, Mager DE, Wainer IW. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol. 2012 Aug;74(2):304-14.
DiazGranados, N, Ibrahim, L, Brutsché, N, et. Al. A randomized add-on trial of an N-methyl-D-aspartate (NMDA) antagonist in treatment –resistant bipolar depression. Archives of General Psychiatry. 2010 Aug;67(8): 793-802.
DiazGranados N, Ibrahim L, Brutsche N, Ameli R, Henter I, Luckenbaugh D, Machado-Vieira R, Zarate CA. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010 Dec;71(12):1605-11.
Machado-Vieria R, Yuan P, Brutsché N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D aspartate antagonist. J Clin Psychiatry. 2009 Dec;71(12):1662-6.
Phelps, LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family History of Alcohol Dependence Predicts and Initial Antidepressant Response to an NMDA Antagonist. Biological Psychiatry. 2009 Jan;65(2):181-4.
Zarate, C.A., Jr., Singh, J.B., Carlson, P., Brutsché, N., Ameli, R., Luckenbaugh, D.A., Charney, D.S., & Manji, H.K. A randomized trial of an NMDA antagonist in treatment resistant major depression. Archives of General Psychiatry. 2006 Aug;63(8): 856-864.